Approved indications
Mexiletine is approved to treat documented, life‑threatening ventricular arrhythmias such as sustained ventricular tachycardia in adults, and is not indicated for benign or asymptomatic ventricular ectopy.

Off‑label uses and evidence
Clinicians sometimes use mexiletine off‑label for certain inherited or acquired conditions involving abnormal heart repolarization (for example, some forms of long QT syndrome or drug‑induced QT prolongation) and for painful diabetic neuropathy or other neuropathic pain syndromes; evidence for these uses is mixed to moderate, and these uses are typically reserved for patients managed by specialists.

Efficacy expectations
When effective for ventricular arrhythmias, mexiletine can reduce the frequency and severity of ventricular tachycardia episodes and premature ventricular contractions, often within days as steady blood levels are reached and doses are adjusted. It is usually used together with other treatments (such as beta‑blockers, implantable cardioverter‑defibrillators, or other antiarrhythmics) rather than alone, and compared with older class I drugs, it is chosen selectively because of a narrow benefit‑risk balance and the general preference for therapies with stronger survival data.

Typical dosing and how to take
For adults with life‑threatening ventricular arrhythmias, common initial dosing is about 200 mg by mouth every 8 hours (600 mg/day), which may be adjusted, often within a range of 200–300 mg every 8 hours (up to a usual maximum around 1,200 mg/day in divided doses), based on clinical response and tolerability. Capsules are swallowed whole with water and are usually taken with food or antacids to reduce stomach upset, at evenly spaced times throughout the day.

Special dosing instructions
Lower starting doses and slower dose increases are typically used in smaller, elderly, or frail adults and in those with liver impairment or significant heart disease. Dose changes should only be made under medical supervision, often guided by symptom control, ECG findings, and, when available, drug level monitoring.

Missed dose guidance
If a dose is missed, it is generally taken as soon as remembered unless it is almost time for the next scheduled dose, in which case the missed dose is skipped and the regular schedule resumed; two doses should not be taken at once to “make up” for a missed dose.

Overdose
Signs of overdose may include severe dizziness, fainting, seizures, very slow or very fast or irregular heartbeat, and loss of consciousness; suspected overdose is a medical emergency and requires immediate contact with emergency services or a poison control center.

Common side effects
Frequent side effects include nausea, heartburn, abdominal discomfort, vomiting, loss of appetite, tremor, dizziness, unsteadiness, headache, and fatigue; these often appear soon after starting or increasing the dose and may lessen as the body adjusts or with taking the medicine with food.

Serious or rare adverse effects
Serious reactions that need urgent medical attention include new or worsening irregular heartbeats, fainting or near‑fainting, chest pain, very slow or very fast heart rate, severe dizziness, confusion, seizures, severe allergic reactions (rash, itching or swelling of face, lips, tongue, or throat, trouble breathing), and signs of liver injury such as persistent nausea, vomiting, right‑upper‑abdominal pain, dark urine, or yellowing of the skin or eyes.

Warnings and precautions
Mexiletine can worsen certain existing arrhythmias or provoke new ones, especially in people with significant structural heart disease, conduction abnormalities, or when combined with other proarrhythmic drugs. Caution and dose adjustment are generally needed in liver impairment; severe liver disease can increase drug levels. Use during pregnancy or breastfeeding requires weighing potential benefits and risks with a clinician, as human data are limited. Safety and dosing in children are not well established and typically limited to specialist use. People with seizure disorders, severe low blood pressure, or significant conduction disease generally need extra caution or alternative therapies.

Comparative safety
Like other class I antiarrhythmic drugs, mexiletine carries a risk of proarrhythmia and has not been shown to improve survival in most patients, so it is used cautiously, usually when safer options are inadequate or not suitable. Regular follow‑up helps balance symptom control with side‑effect risk.

Reporting side effects and safety updates
Patients in the United States can report suspected side effects to the FDA MedWatch program or through their healthcare professional or pharmacist, and up‑to‑date safety information is available from the FDA and manufacturer‑provided prescribing information.

Drug and supplement interactions
Mexiletine is metabolized mainly in the liver and can interact with other medicines that affect certain liver enzymes or cardiac conduction. Examples include some antiarrhythmics (such as quinidine, flecainide, or lidocaine), beta‑blockers, certain antidepressants, antipsychotics, and drugs that significantly slow heart conduction or prolong the QT interval. Some seizure medicines, antibiotics, and antifungal agents may raise or lower mexiletine blood levels. Alcohol can increase side effects like dizziness and may affect heart rhythm, so intake is usually limited or avoided. Patients should review all prescription medicines, over‑the‑counter drugs, and supplements (including herbal products) with their clinician or pharmacist.

Food and lifestyle interactions
Taking mexiletine with food often improves stomach tolerance, and maintaining a consistent routine with meals can help keep drug levels steady. Excess caffeine or other stimulants may worsen palpitations or tremor in some individuals and may need to be reduced.

Precautions and conditions requiring caution
Use is generally avoided or used with great caution in people with untreated second‑ or third‑degree heart block without a pacemaker, cardiogenic shock, severe sinus‑node dysfunction, markedly low blood pressure, or a history of serious drug‑induced arrhythmias. Extra care is needed when mexiletine is combined with other drugs that depress heart conduction or have known proarrhythmic or QT‑prolonging effects. Liver disease, seizure disorders, and significant electrolyte disturbances (such as low potassium or magnesium) should be addressed and monitored closely.

Monitoring needs
Before and during therapy, clinicians typically monitor heart rhythm with ECGs, blood pressure, and clinical symptoms to detect proarrhythmia or conduction problems. Periodic blood tests may be done to check liver function and, in some settings, mexiletine blood levels, especially in patients with liver disease, interacting drugs, or unexplained side effects or lack of efficacy.

Q: What is mexiletine used for?
A: Mexiletine is used mainly to help control documented, life‑threatening abnormal heart rhythms that start in the lower chambers of the heart (ventricles), typically in adults under the care of a heart rhythm specialist.

Q: How long does it take for mexiletine to start working?
A: Mexiletine begins affecting heart rhythm soon after dosing, but doctors usually assess benefit over days to weeks while adjusting the dose and monitoring heart rhythm and symptoms.

Q: Can I drink alcohol while taking mexiletine?
A: Alcohol can increase dizziness and may affect heart rhythm, so many clinicians recommend avoiding or limiting alcohol and discussing any regular use before or during treatment.

Q: Do I need regular tests while on mexiletine?
A: Yes, your healthcare team will typically order periodic ECGs and other checks, and sometimes blood tests, to monitor your heart rhythm, blood pressure, liver function, and overall response to treatment.

Q: Can I stop mexiletine if I feel better?
A: Do not stop mexiletine on your own; stopping suddenly can allow serious abnormal rhythms to return, so any change in dose or discontinuation should be planned and supervised by your heart specialist.

Storage
Store mexiletine capsules at room temperature (generally 68–77°F or 20–25°C), protected from excessive heat, moisture, and light, and keep the bottle tightly closed and out of reach of children and pets.

Disposal
Do not flush mexiletine down the toilet or pour it into drains unless instructed; instead, use a local drug take-back program or follow pharmacist or community guidelines for mixing unused capsules with undesirable household waste (such as used coffee grounds or kitty litter) in a sealed container before throwing in the trash, after removing or obscuring personal information on the label.